Literature DB >> 9930320

A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes.

M E Weijtens1, R A Willemsen, E H Hart, R L Bolhuis.   

Abstract

Genetic engineering of T lymphocytes for adoptive clinical immunotherapy calls for efficient gene transduction methods. Therefore, a transient retroviral gene transduction system 'STITCH' was developed comprising pSTITCH retroviral vector encoding the transgene, plasmids encoding Moloney murine leukemia virus gag/pol and gibbon ape leukemia virus envelope, and the human kidney cell line 293T as a packaging line. Cotransfection of retroviral vector and packaging plasmids in 293T cells results in the production of GALV env pseudotyped viral particles with a titer of 10(7) infectious units per milliliter. The 'STITCH' gene transduction system efficiently transduces genes into activated human T lymphocytes derived from healthy donors and cancer patients. The efficacy of gene transduction is donor-independent. A direct application of the 'STITCH' gene transduction system is the genetic engineering of activated human T lymphocytes to induce expression of antibody based chimeric receptors in their membrane. Introduction of these chimeric receptors into activated human T lymphocytes graft these cells with specificity for, for example, renal cell carcinoma. In order to study the effect of the chimeric receptor gene structure on the processes ultimately leading to functional membrane expression, we designed a number of different chimeric receptor gene structures and subsequently compared their membrane expression on 293T cells and activated human T lymphocytes. Distinct membrane expression densities were observed on 293T cells and human T lymphocytes for the different chimeric receptor gene constructs. Gene transduction of activated human T lymphocytes with four out of five chimeric receptor gene constructs resulted in functional expression of chimeric receptor as demonstrated by specific recognition and cytolysis of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930320     DOI: 10.1038/sj.gt.3300696

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  17 in total

1.  The cellular protein lyric interacts with HIV-1 Gag.

Authors:  Christine E Engeland; Heike Oberwinkler; Michael Schümann; Eberhard Krause; Gerd A Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

3.  Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454

4.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

Authors:  Jehonathan H Pinthus; Tova Waks; Victoria Malina; Keren Kaufman-Francis; Alon Harmelin; Itzhak Aizenberg; Hannah Kanety; Jacob Ramon; Zelig Eshhar
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

Authors:  A Hombach; C Schlimper; E Sievers; S Frank; H H Schild; T Sauerbruch; I G H Schmidt-Wolf; H Abken
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

6.  Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2019-06-19       Impact factor: 11.454

7.  Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells.

Authors:  Ronen Borenstein; Oded Singer; Adi Moseri; Niza Frenkel
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 8.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

9.  Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Authors:  Andreas A Hombach; André Görgens; Markus Chmielewski; Florian Murke; Janine Kimpel; Bernd Giebel; Hinrich Abken
Journal:  Mol Ther       Date:  2016-04-26       Impact factor: 11.454

10.  Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammation.

Authors:  Valentina Ugalde; Francisco Contreras; Carolina Prado; Ornella Chovar; Alexandra Espinoza; Rodrigo Pacheco
Journal:  Mucosal Immunol       Date:  2020-11-12       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.